Clinical trials: Demyelinating Diseases
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Ulcerative Colitis
Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
The goal of this clinical trial is to learn how Ozanimod drug can be administered to the healthy subjects via transdermal delivery system (TDS, patch) to achieve better drug absorption and delivery than via oral capsules…
- Trial name
- NCT06528665
- Testing
- ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
- Where
- Malaysia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Multiple Sclerosis
Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients
Sufficient subjects with a confirmed diagnosis of MS (EDSS score of 6.5 or below), will be recruited to ensure that 30 subjects (approx. equal numbers of each gender) complete the study.
- Trial name
- NCT00548769
- Testing
- Formulation A, Formulation B, Formulation C
- Where
- 4 sites in Czechia, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
- Trial name
- SPI2 (NCT02936037)
- Testing
- MD1003 100mg capsule
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 642 people
- Sponsor
- MedDay Pharmaceuticals SA
Multiple Sclerosis, Relapsing-Remitting
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
The present study aims to assess the adherence to therapy with interferon beta-1a (Rebif®) and at investigating potential factors that are involved in its outcome, in a representative sample of patients with relapsing remitting…
- Trial name
- NCT01112345
- Where
- Greece
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers
This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state.
- Trial name
- NCT05983939
- Testing
- PIPE-791
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Multiple Sclerosis
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
- Trial name
- OPTIMUM (NCT02425644)
- Testing
- ponesimod, teriflunomide
- Where
- 162 sites in United States, Belarus and 26 more
- Volunteers
- 1,133 people
- Sponsor
- Actelion
Relapsing Remitting Multiple Sclerosis
An Extension of the TG1101-RMS201 Trial
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT03381170
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- TG Therapeutics, Inc.
Progressive Multiple Sclerosis
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
- Trial name
- MAXIMS (NCT05441488)
- Testing
- Masitinib (4.5)
- Where
- 37 sites in France, Greece and 6 more
- Volunteers
- 800 people
- Sponsor
- AB Science
Multiple Sclerosis, Relapsing-Remitting
Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis
An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, versus Avonex® (Biogen Idec Ltd., UK) in Patients…
- Trial name
- NCT02744222
- Testing
- BCD-054 180 mcg, Avonex®, BCD-054 240 mcg
- Where
- Russia
- Volunteers
- 399 people
- Sponsor
- Biocad
Multiple Sclerosis, Relapsing-Remitting
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.
RebiSmart™ is a device with an electronic injection log to monitoring adherence to therapy. Therefore RebiSmart is a tool for administering Rebif in multi-dose cartridges that may improve patient satisfaction and adherence to…
- Trial name
- SMART (NCT01108887)
- Where
- Netherlands
- Volunteers
- 912 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Demonstrate the bioequivalence of a serum-free solution to a serum containing solution of Avonex.
- Trial name
- NCT00913250
- Testing
- Serum containing Avonex, Serum Free Avonex
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis (MS)
MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study
The primary objective of this sub-study is to supplement the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) dataset with coronavirus disease 2019 (COVID-19)-related health information obtained…
- Trial name
- NCT05058729
- Where
- 6 sites in United States
- Volunteers
- 1,507 people
- Sponsor
- Biogen
Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
The objectives of this study are to explore the effects of administering high-dose corticosteroids to participants who developed progressive multifocal leukoencephalopathy (PML) while on natalizumab as measured by time-course…
- Trial name
- IRIS (NCT01211665)
- Testing
- Methylprednisolone, Prednisolone
- Where
- 3 sites in United States, Germany
- Volunteers
- 3 people
- Sponsor
- Biogen
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06677710
- Testing
- IDP-023, Ocrelizumab, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Indapta Therapeutics, INC.
Relapsing Multiple Sclerosis
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms…
- Trial name
- PROVIDE (NCT06143514)
- Testing
- No intervention
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis, Relapsing-Remitting
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a 3-part study where Parts A, B (single-blind - investigator and subject blind) will enrol healthy volunteers and Part C (open-label) will enrol RRMS patients.
- Trial name
- NCT01808482
- Testing
- Part A: 100 mg/mL GSK2618960, Part B: Dose of GSK2618960 decided from Part A, Part C: Dose of GSK2618960 decided from Part A and B
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of…
- Trial name
- FREXALT (NCT06141473)
- Testing
- Frexalimab, Teriflunomide, MRI contrast-enhancing agents
- Where
- 382 sites in United States, Argentina and 39 more
- Volunteers
- 1,655 people
- Sponsor
- Sanofi
Multiple Sclerosis, Relapsing-Remitting
IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study
The IMCY-MS-001 study is a study to test a new experimental drug, IMCY-0141, for the treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS).
- Trial name
- NCT05417269
- Testing
- IMCY-0141, Dimethyl Fumarate
- Where
- Moldova
- Volunteers
- 150 people
- Sponsor
- Imcyse SA
Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
- Trial name
- NCT01892722
- Testing
- Interferon beta-1a, Fingolimod
- Where
- 73 sites in United States, Australia and 23 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.